463 related articles for article (PubMed ID: 11730719)
21. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A.
Darmani NA
Neuropsychopharmacology; 2001 Feb; 24(2):198-203. PubMed ID: 11120402
[TBL] [Abstract][Full Text] [Related]
22. Dual intracellular signaling pathways mediated by the human cannabinoid CB1 receptor.
Calandra B; Portier M; Kernéis A; Delpech M; Carillon C; Le Fur G; Ferrara P; Shire D
Eur J Pharmacol; 1999 Jun; 374(3):445-55. PubMed ID: 10422789
[TBL] [Abstract][Full Text] [Related]
23. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
Sugiura T; Kondo S; Kishimoto S; Miyashita T; Nakane S; Kodaka T; Suhara Y; Takayama H; Waku K
J Biol Chem; 2000 Jan; 275(1):605-12. PubMed ID: 10617657
[TBL] [Abstract][Full Text] [Related]
24. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells.
Di Marzo V; Melck D; Orlando P; Bisogno T; Zagoory O; Bifulco M; Vogel Z; De Petrocellis L
Biochem J; 2001 Aug; 358(Pt 1):249-55. PubMed ID: 11485574
[TBL] [Abstract][Full Text] [Related]
25. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid pharmacology: implications for additional cannabinoid receptor subtypes.
Wiley JL; Martin BR
Chem Phys Lipids; 2002 Dec; 121(1-2):57-63. PubMed ID: 12505690
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid.
Laine K; Järvinen K; Mechoulam R; Breuer A; Järvinen T
Invest Ophthalmol Vis Sci; 2002 Oct; 43(10):3216-22. PubMed ID: 12356827
[TBL] [Abstract][Full Text] [Related]
28. Attenuation of nerve growth factor-induced visceral hyperalgesia via cannabinoid CB(1) and CB(2)-like receptors.
Farquhar-Smith WP; Jaggar SI; Rice AS
Pain; 2002 May; 97(1-2):11-21. PubMed ID: 12031775
[TBL] [Abstract][Full Text] [Related]
29. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo.
Bisogno T; Melck D; Bobrov MYu ; Gretskaya NM; Bezuglov VV; De Petrocellis L; Di Marzo V
Biochem J; 2000 Nov; 351 Pt 3(Pt 3):817-24. PubMed ID: 11042139
[TBL] [Abstract][Full Text] [Related]
30. Stimulation of cannabinoid (CB1) and prostanoid (EP2) receptors opens BKCa channels and relaxes ocular trabecular meshwork.
Stumpff F; Boxberger M; Krauss A; Rosenthal R; Meissner S; Choritz L; Wiederholt M; Thieme H
Exp Eye Res; 2005 May; 80(5):697-708. PubMed ID: 15862177
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of cannabinoid receptor agonists and antagonists using the guanosine-5'-O-(3-[35S]thio)-triphosphate binding assay in rat cerebellar membranes.
Griffin G; Atkinson PJ; Showalter VM; Martin BR; Abood ME
J Pharmacol Exp Ther; 1998 May; 285(2):553-60. PubMed ID: 9580597
[TBL] [Abstract][Full Text] [Related]
32. Agonist-dependent cannabinoid receptor signalling in human trabecular meshwork cells.
McIntosh BT; Hudson B; Yegorova S; Jollimore CA; Kelly ME
Br J Pharmacol; 2007 Dec; 152(7):1111-20. PubMed ID: 17922024
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoids and the human uterus during pregnancy.
Dennedy MC; Friel AM; Houlihan DD; Broderick VM; Smith T; Morrison JJ
Am J Obstet Gynecol; 2004 Jan; 190(1):2-9; discussion 3A. PubMed ID: 14749627
[TBL] [Abstract][Full Text] [Related]
34. Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid receptors.
Lambert DM; DiPaolo FG; Sonveaux P; Kanyonyo M; Govaerts SJ; Hermans E; Bueb J; Delzenne NM; Tschirhart EJ
Biochim Biophys Acta; 1999 Sep; 1440(2-3):266-74. PubMed ID: 10521710
[TBL] [Abstract][Full Text] [Related]
35. The CB1 cannabinoid receptor is coupled to the activation of protein kinase B/Akt.
Gómez del Pulgar T; Velasco G; Guzmán M
Biochem J; 2000 Apr; 347(Pt 2):369-73. PubMed ID: 10749665
[TBL] [Abstract][Full Text] [Related]
36. Activation of spinal cannabinoid 1 receptors inhibits C-fibre driven hyperexcitable neuronal responses and increases [35S]GTPgammaS binding in the dorsal horn of the spinal cord of noninflamed and inflamed rats.
Drew LJ; Harris J; Millns PJ; Kendall DA; Chapman V
Eur J Neurosci; 2000 Jun; 12(6):2079-86. PubMed ID: 10886347
[TBL] [Abstract][Full Text] [Related]
37. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions.
Bouaboula M; Perrachon S; Milligan L; Canat X; Rinaldi-Carmona M; Portier M; Barth F; Calandra B; Pecceu F; Lupker J; Maffrand JP; Le Fur G; Casellas P
J Biol Chem; 1997 Aug; 272(35):22330-9. PubMed ID: 9268384
[TBL] [Abstract][Full Text] [Related]
38. Anandamide induces overeating: mediation by central cannabinoid (CB1) receptors.
Williams CM; Kirkham TC
Psychopharmacology (Berl); 1999 Apr; 143(3):315-7. PubMed ID: 10353436
[TBL] [Abstract][Full Text] [Related]
39. The potent emetogenic effects of the endocannabinoid, 2-AG (2-arachidonoylglycerol) are blocked by delta(9)-tetrahydrocannabinol and other cannnabinoids.
Darmani NA
J Pharmacol Exp Ther; 2002 Jan; 300(1):34-42. PubMed ID: 11752094
[TBL] [Abstract][Full Text] [Related]
40. Noladin ether acts on trabecular meshwork cannabinoid (CB1) receptors to enhance aqueous humor outflow facility.
Njie YF; Kumar A; Qiao Z; Zhong L; Song ZH
Invest Ophthalmol Vis Sci; 2006 May; 47(5):1999-2005. PubMed ID: 16639008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
